We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Clot Protection Benefits Evaluated for New Blood Gas Testing System

By LabMedica International staff writers
Posted on 12 Sep 2012
The clot protection capabilities of a new blood gas testing system have been highlighted in an evaluation undertaken at a hospital intensive care unit.

Blood sample clotting is a main concern in point-of-care (POC) testing systems (particularly in neonates for whom blood gases are the most common test performed) and can lead to delayed results and treatment, inconvenient analyzer downtime, and increased work and stress for hospital staff. More...
At the intensive care unit of Stepping Hill Hospital of Stockport NHS Foundation Trust (Stockport, UK), 175 patient samples, including about 30 considered “high risk” for clotting, were analyzed in an evaluation of the new “Roche cobas b 123 POC” system from Roche Diagnostics (Basel, Switzerland). The tests were performed by nursing staff; quality control testing was performed automatically by AutoQC twice daily.

“We never had a problem with clots throughout the entire evaluation, despite using a wide variety of samples of varying condition and age,” said Samantha Ekin, Point of Care Coordinator (PCC) at the Trust. “This will be vital in a delivery suite setting where the quality of samples can be lower. The small size of the analyzer is great as it can be housed more easily, and it is portable.”

The cobas b 123 is specifically designed to eliminate risk of clot blockages. A new clot clearance feature prevents movement of clots from the syringe or capillary into the analyzer. This is achieved using a dual-action preanalytical barrier, with bottlenecks in the sample port needle and the cooximetry measuring chamber, so that clots are simply rinsed away with the sample by the automated default washing routine. Built-in optical sensors detect whether the lack of fluid path flow is due to a clot, in which case a series of automated expulsion steps remove the clot before continuing analysis uninterrupted.

To date, in both internal and external ongoing evaluations, no downtime owing to clots has been reported for the Roche cobas b 123 POC. The system is very easy to use and requires very little maintenance. “The whole process of analyzing a patient sample was very easy for the operator,” PPC Ekin continues; “This is very important because if the nurses like the analyzer they will have confidence to use it and confidence in the results. The low maintenance is also extremely important, especially for ‘out of hours’ work, as it enables the operators to perform any maintenance that might be required.” She adds that since training is very simple and requires less time, the procedure would be more accessible to additional staff.

Related Links:
Roche Diagnostics
Stockport NHS Foundation Trust


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.